BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

SHR-A1811: trial readouts and FDA decisions

4 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 4 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06840002 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerOvarian Cancerrecruiting150
2026-12-31 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT05424835 A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously TreatedHER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzactive not recruiting381
2026-12-31 est.P2Jiangsu HengRui Medicine Co., Ltd.NCT06413745 Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract CanHER2 Expression / Amplification in Patients With Biliary Tract Canceractive not recruiting59
2026-12 est.P1/P2Jiangsu HengRui Medicine Co., Ltd.NCT05482568 A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerAdvanced Non-small Cell Lung Cancerrecruiting324

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10 est.P1/P2Shanghai Shengdi Pharmaceutical Co., LtdNCT07231211 A Study of SHR-4610 Injection in Patients With Advanced Solid TumorsSolid Tumorsrecruiting258
2026-10 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06859775 SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical CancerRecurrent or Metastatic Cervical Cancerrecruiting100
2026-08 est.P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07110571 A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ CancerGastric Cancer; Gastroesophageal-junction Cancerrecruiting200
2026-07-15P3Jiangsu HengRui Medicine Co., Ltd.NCT06057610 A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast CancerHER2-PositiveRecurrent or Metastatic Breast Canceractive not recruiting868

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.